Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring and acceleration of healing, today announces that effective from 1 August 2008 Mr David Blain will join the Renovo Executive Team and Board as its interim Chief Financial Officer and Company Secretary replacing Mr Robin Cridland who is joining Revolymer Limited as its Chief Financial Officer and Company Secretary.
Mr Blain, aged 46, has been operating his own consultancy for the past year. Prior to this Mr Blain was finance director and company secretary at Drew Scientific Group plc and latterly at eg Solutions plc. Mr Blain trained as a chartered accountant at WT Walton & Son before serving nine years at PriceWaterhouseCoopers. Mr Blain is a member of the Institute of Chartered Accountants.
Rodger Pannone, Chairman of Renovo, said:
“We are delighted to welcome David to the Company. The Board would also like to thank Rob for his sound advice and significant contribution over the past seven years during which time Renovo has evolved from a private to public entity. Whilst we are sorry to see Rob leave we understand that he wishes to put his experience to use at another private company. We wish him well for the future.”